Indivior PLC (LON:INDV) had its price target hoisted by Morgan Stanley from GBX 320 ($4.21) to GBX 410 ($5.39) in a research note published on Thursday. They currently have an equal weight rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on INDV. Citigroup Inc. upgraded Indivior PLC to a buy rating and boosted their price objective for the company from GBX 280 ($3.68) to GBX 490 ($6.44) in a report on Wednesday, November 8th. Jefferies Group LLC boosted their price objective on Indivior PLC from GBX 490 ($6.44) to GBX 540 ($7.10) and gave the company a buy rating in a report on Friday, August 11th. Royal Bank Of Canada raised Indivior PLC to an outperform rating and lifted their target price for the company from GBX 390 ($5.13) to GBX 470 ($6.18) in a research report on Friday, July 28th. Numis Securities Ltd reaffirmed a buy rating and set a GBX 470 ($6.18) target price on shares of Indivior PLC in a research report on Friday, September 15th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a GBX 400 ($5.26) target price on shares of Indivior PLC in a research report on Friday, September 15th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of GBX 448.14 ($5.89).

Indivior PLC (INDV) opened at GBX 378.30 ($4.98) on Thursday. Indivior PLC has a 1-year low of GBX 246.50 ($3.24) and a 1-year high of GBX 421.50 ($5.54).

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/13/indivior-plc-indv-price-target-raised-to-gbx-410-at-morgan-stanley.html.

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.